Fulcrum Therapeutics (NASDAQ:FULC) Director Rock Ventures Iii L.P. Third acquired 61,280 shares of the stock in a transaction dated Friday, July 19th. The stock was bought at an average price of $17.79 per share, with a total value of $1,090,171.20.

Shares of FULC traded down $0.31 during trading hours on Monday, reaching $11.66. The stock had a trading volume of 664 shares, compared to its average volume of 70,589. The stock’s 50-day moving average is $11.60. Fulcrum Therapeutics has a 12 month low of $8.19 and a 12 month high of $15.94.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings results on Monday, August 26th. The company reported ($9.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($3.10) by ($6.11). Analysts anticipate that Fulcrum Therapeutics will post -2.77 earnings per share for the current fiscal year.

Several brokerages recently issued reports on FULC. Morgan Stanley initiated coverage on shares of Fulcrum Therapeutics in a research note on Monday, August 12th. They set an “overweight” rating and a $29.00 target price on the stock. Svb Leerink reiterated an “outperform” rating on shares of Fulcrum Therapeutics in a report on Monday, August 12th. Finally, Bank of America began coverage on shares of Fulcrum Therapeutics in a research report on Monday, August 12th. They set a “buy” rating and a $19.00 price objective on the stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia.

See Also: Why is Cost of Capital Important?

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.